Arvinas, Inc.
NASDAQ:ARVNBiotechnology
-$0.10 today
- Market cap
- $443.01M
- Beta
- 1.75
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$3.46
Volume 1.09M
Average 0.89M
ARVN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Arvinas, Inc.NASDAQ: ARVN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.1M fell 15.4% year over year, ahead of the -19.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 8.3% from the prior quarter. Over 3 fiscal years it compounded at -14.1% a year.
Context
- Depreciation & amortization amounted to 2.0% of revenue in FY2025, down 0.5 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -15.4% holds above the trailing-twelve-month pace of -19.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 5.2M USD
- Year-over-year change
- -21.2%
- 4-year CAGR
- -3.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.2M | -21.2% |
| FY2024 | 2024-12-31 | 6.6M | -1.5% |
| FY2023 | 2023-12-31 | 6.7M | -18.3% |
| FY2022 | 2022-12-31 | 8.2M | +36.7% |
| FY2021 | 2021-12-31 | 6M | — |
Depreciation & Amortization vs competitors
How ARVN compares with its peers on the latest reported figures
- ARVN's LTM Mar 2026 depreciation & amortization of $5M is the 4th largest of the 6 companies compared; the peer median is $8.23M.
- Its year-over-year change of -19.4% is the lowest of 6, against a peer median of +0.8%.
- Depreciation & amortization amounts to 5.6% of revenue for ARVN, versus a peer median of 9.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $15.87M | -14.3% | +20.4% | 2.3% | |
| LTM Mar 2026 | $8.34M | +0.8% | +30.7% | 19.4% | |
| LTM Jun 2026 | $8.23M | +1.6% | +40.8% | 7.8% | |
| LTM Mar 2026 | $5M | -19.4% | -14.1% | 5.6% | |
| LTM Mar 2026 | $3.38M | +84.9% | +5.3% | 9.7% | |
| LTM Mar 2026 | $2.84M | -8.0% | -25.0% | 10.1% | |
| Peer median (excluding ARVN) | $8.23M | +0.8% | +20.4% | 9.7% | |
Competitors are the stored peer set for ARVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (191M) | (282.5M) | (367.3M) | (198.9M) | (80.8M) |
| Depreciation & Amortization | 6M | 8.2M | 6.7M | 6.6M | 5.2M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 57.1M | 75.5M | 71.6M | 88.2M | 44M |
| Change in Working Capital | 678.3M | (82.6M) | (44.4M) | (140.6M) | (233.7M) |
| Accounts Receivables | (30.2M) | 14M | 800K | (5.7M) | 7.3M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 27.9M | 20.2M | 17.3M | (21.2M) | (1.7M) |
| Other Working Capital | 680.6M | (116.8M) | (62.5M) | (113.7M) | (239.3M) |
| Other Non-Cash Items | 9M | 7.9M | (14.4M) | (14.6M) | (8.5M) |
| Operating Cash Flow | 559.4M | (273.5M) | (347.8M) | (259.3M) | (273.8M) |
| Capital Expenditures | (4.7M) | (6.8M) | (2.9M) | (1.8M) | (1.9M) |
| Acquisitions (Net) | 0 | 400K | 0 | 100K | 0 |
| Purchases of Investments | (1.74B) | (886.4M) | (956.3M) | (652.1M) | (354.2M) |
| Sales of Investments | 435.7M | 1.14B | 1.16B | 688.5M | 763.7M |
| Other Investing Activities | 0 | (400K) | 0 | 0 | 0 |
| Investing Cash Flow | (1.31B) | 242.8M | 203.5M | 34.7M | 407.6M |
| Debt Repayment | 0 | 0 | 0 | (400K) | (200K) |
| Common Stock Issued | 264.6M | 4.7M | 387.2M | 8.3M | 700K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (91.9M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 14M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 278.6M | 4.7M | 374.7M | 7.9M | (91.4M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (475.6M) | (26M) | 230.4M | (216.7M) | 42.4M |
| Free Cash Flow | 554.7M | (280.3M) | (350.7M) | (261.1M) | (275.7M) |
Arvinas, Inc.
NASDAQ:ARVN
Intrinsic Alpha fair value
Locked
Current Price
$6.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.